However I do not believe that Silviu would sell the heart asset as it’s something which he is passionate about and wants to lead it through to commercialization (in my opinion), most probably with a partner. With regards to the confirmatory Phase 3 trial, the NIH heart network had already agreed to fund it. Mesoblast said in attached presentation (link below) that NIH had agreed to fund the confirmatory phase 3 trial for End-Stage Heart Failure. Mesoblast wrote: “Mesoblast and the International Center for Health Outcomes Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai in New York have agreed on a confirmatory Phase 3 trial of REVASCOR in patients with end-stage heart failure and a LVAD, in line with FDA guidance. REVASCOR is being developed for these patients under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations.”
(20min delay)